NCT01893268 is a clinical trial in Non-Squamous Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche.

Who is sponsoring NCT01893268?

NCT01893268 is sponsored by Hoffmann-La Roche.

What condition does NCT01893268 study?

NCT01893268 studies Non-Squamous Non-Small Cell Lung Cancer.

Is NCT01893268 still recruiting?

NCT01893268 is currently completed. Last updated 14 May 2018.

Last reviewed 2018-05-14 · How we verify

NCT01893268

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice

Completed Last updated 14 May 2018

What this trial tests

trial in Non-Squamous Non-Small Cell Lung Cancer in 279 participants. Completed in 20 March 2018.

Timeline

25 July 2013

Primary endpoint
20 March 2018

20 March 2018

Quick facts

Lead sponsor	Hoffmann-La Roche
Status	Completed
Study type	OBSERVATIONAL
Enrollment	279
Start date	25 July 2013
Primary completion	20 March 2018
Estimated completion	20 March 2018
Sites	88 locations across France

Conditions studied

Non-Squamous Non-Small Cell Lung Cancer — all drugs for Non-Squamous Non-Small Cell Lung Cancer →

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

65 and older, any sex, with Non-Squamous Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective, observational study will assess the effectiveness and safety of Avastin (bevacizumab) as 1st line therapy in elderly patients with advanced non-squamous non-small cell lung cancer in clinical practice. Therapy with Avastin and standard chemotherapy will be administered according to the treating physician. Data will be collected for approximately 4 years.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Non-Squamous Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06417008 — A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer · Phase 2, PHASE3 · recruiting

Other Hoffmann-La Roche trials

Trials by the same sponsor.

NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01893268 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 14 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01893268.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing